PDE

PDE-IN-3 is a phosphodiesterase (PDE) inhibitor exhibiting an IC50 value of 260 μM. This compound effectively modulates the breakdown of cyclic nucleotides, making it a valuable tool for investigating intracellular signaling pathways. PDE-IN-3 is applicable in research areas such as cardiovascular biology, neurobiology, and cancer research, where PDE inhibitors play a critical role in therapeutic strategies.

UK 357903 is a selective inhibitor of phosphodiesterase 5 (PDE5), exhibiting IC50 values of 1.7 nM for PDE5 and 714 nM for PDE6. This compound demonstrates significant vasodilatory effects in mesenteric and hindlimb vascular beds, making it a promising candidate for research applications related to erectile dysfunction and vascular smooth muscle relaxation. Its mechanism of action provides a valuable tool for investigating PDE5-related pathways in various physiological and pathological contexts.

PDE4-IN-25 is a potent phosphodiesterase 4 (PDE4) inhibitor, exhibiting an IC50 value of 0.1 μM. This compound is significant in the study of inflammatory diseases, as it regulates intracellular cyclic nucleotide levels, thereby influencing inflammatory response pathways. PDE4-IN-25 is valuable for researchers investigating therapeutic interventions for conditions characterized by dysregulated inflammation.

LEO 29102 is a potent inhibitor of phosphodiesterase 4 (PDE4) with an IC50 value of 5 nM. This compound effectively inhibits the release of TNFα, making it a valuable tool for studies related to inflammatory responses. LEO 29102 shows promise in the research of atopic dermatitis and other related conditions associated with PDE4 activity.

2'-O-MB-cGMP sodium is a cyclic GMP-specific phosphodiesterase inhibitor with an I50 value of 35 µM. It effectively inhibits the hydrolysis of cyclic nucleotides by Ca2+-dependent phosphodiesterases, utilizing cAMP or cGMP as substrates. This compound is invaluable in research focused on cyclic nucleotide signaling pathways and can aid in the study of vascular smooth muscle function, platelet aggregation, and a range of physiological processes influenced by cyclic GMP.

T-0156 free base is a selective inhibitor of phosphodiesterase type 5 (PDE5), functioning through competitive inhibition of cyclic guanosine monophosphate (cGMP) hydrolysis, with an IC50 of 0.23 nM. In addition to its primary target, T-0156 exhibits some inhibitory activity against PDE6 with an IC50 of 56 nM, while demonstrating low potency against other PDEs, including PDE1, PDE2, PDE3, and PDE4 (IC50 > 10 μM). This compound plays a valuable role in enhancing the nitric oxide (NO)/cGMP signaling pathway, making it suitable for research in vascular biology and therapies related to erectile dysfunction and pulmonary hypertension.

Irsogladine maleate is a phosphodiesterase 4 (PDE4) inhibitor that enhances intracellular cyclic adenosine monophosphate (cAMP) levels. This compound exhibits anti-inflammatory properties and is primarily utilized in research focused on chronic inflammatory diseases and gastric protection mechanisms. Additionally, its affinity for muscarinic acetylcholine receptors may provide insights into neuroprotective effects and gastrointestinal motility studies.

Adibendan (BM 14478) is a selective phosphodiesterase III (PDE III) inhibitor, exhibiting an IC50 value of 2.0 μM. With over 60-fold selectivity compared to PDE I and II inhibitors, Adibendan functions as a novel cardiotonic agent. This compound is valuable for researchers investigating cardiovascular diseases and exploring the modulation of cardiac contractility through PDE III inhibition.

Mardepodect precursor is the chemical precursor of Mardepodect, a selective inhibitor targeting phosphodiesterase 10A (PDE10A). This compound exhibits potent inhibitory activity with an IC50 of 0.37 nM and displays greater than 1000-fold selectivity over other phosphodiesterases. Mardepodect and its precursor are integral for research into neuropsychiatric disorders, promoting the understanding of PDE10A's role in central nervous system functions.

LY 186126 is a potent phosphodiesterase (PDE) inhibitor that acts by targeting cardiac sarcoplasmic reticulum PDE with a high binding affinity (Kd = 5.6 nM). This compound is utilized in research related to cardiac function and signaling pathways by modulating cyclic nucleotide levels, making it valuable for studies on cardiovascular conditions and PDE-related mechanisms.

Quazodine is a potent phosphodiesterase (PDE) inhibitor that modulates intracellular cAMP and cGMP levels. Its primary activity involves vasodilatory effects, making it a valuable tool in studies related to vascular smooth muscle function. Quazodine is suitable for research applications exploring cardiovascular diseases and smooth muscle physiology.

K-252d is an indolocarbazole alkaloid that acts primarily as a phosphodiesterase (PDE) inhibitor. It demonstrates significant inhibitory activity against calcium- and calmodulin-dependent phosphodiesterase isolated from bovine heart, with an IC50 of 46.2 μM, and is also recognized for its role as a protein kinase C (PKC) inhibitor, exhibiting an IC50 of 350 nM against PKC isolated from rat brain. This compound is valuable for studies related to signal transduction pathways and therapeutic interventions targeting PDE-related disorders.

6-Cl-cPuMP sodium is a cAMP analog that acts as a phosphodiesterase (PDE) stabilizer. This compound exhibits excellent membrane permeability, allowing for effective cellular uptake, while maintaining stability against PDE degradation. 6-Cl-cPuMP sodium is particularly useful in research related to the nervous system, enabling studies of cAMP signaling pathways and their implications in neurobiology.

Cipamfylline is a potent inhibitor of phosphodiesterase 4 (PDE4), specifically facilitating the accumulation of PDE4A4 within distinct cellular regions via its interaction with the ubiquitin scaffolding protein p62. This compound plays a critical role in research focused on atopic dermatitis, contributing to the understanding of inflammatory pathways and potential therapeutic interventions in this condition.

ONO-6126 is a selective phosphodiesterase 4 (PDE4) inhibitor with potential therapeutic applications in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By inhibiting PDE4, it increases intracellular cAMP levels, which can help reduce inflammation and bronchoconstriction. This compound is valuable for research focused on understanding the molecular mechanisms of respiratory conditions and testing novel therapeutic strategies.

Braylin is a potent phosphodiesterase-4 (PDE4) inhibitor that plays a significant role in anti-inflammatory and immunomodulatory processes. It is particularly relevant in the exploration of immunoinflammatory diseases, making it a valuable tool for researchers studying these conditions. Its ability to modulate inflammatory responses positions it as a potential therapeutic target in related research applications.

RS-25344 is a selective inhibitor of phosphodiesterase type IV (PDE4), which plays a crucial role in the degradation of cyclic adenosine monophosphate (cAMP). By inhibiting PDE4 activity, RS-25344 promotes increased intracellular cAMP levels, contributing to an array of biological responses. This compound is valuable for research in inflammation, immune disorders, neurodegenerative diseases, and cardiovascular conditions. Its ability to modulate cAMP signaling makes it a significant tool for exploring therapeutic strategies in these areas.

Desmethyl thiosildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. This compound exhibits significant biological activity by promoting vasodilation through the inhibition of PDE5, thereby enhancing nitric oxide signaling. It is commonly used in research applications focused on cardiovascular function and erectile dysfunction, providing insights into the therapeutic potential for related disorders.

JNJ-10258859 is a highly selective phosphodiesterase type 5 (PDE5) inhibitor, exhibiting a Ki value of 0.23 nM. This compound effectively elevates cyclic GMP levels, which is crucial for promoting smooth muscle relaxation and improving erectile function. JNJ-10258859 is primarily utilized in research focused on erectile dysfunction and related cardiovascular studies.

5,6-DM-cBIMP is a cyclic nucleotide analog that serves as an agonist for phosphodiesterase 2 (PDE2). It is capable of significantly enhancing the hydrolytic activities of cAMP and cGMP by PDE2, making it a valuable tool for researchers investigating the modulation of cyclic nucleotide signaling pathways. Its application is particularly relevant in studies focused on cardiovascular and neurological research.

MMPX is a potent phosphodiesterase type 1 (PDE1) inhibitor that modulates intracellular signaling pathways by increasing cyclic nucleotide levels. This compound exhibits significant biological activity in various cellular processes, making it a valuable tool for studying the physiological roles of PDE1 in neurological and cardiovascular research. Its application extends to exploring therapeutic strategies for diseases associated with dysregulated cyclic nucleotide signaling.

BMS-341400 mesylate is a selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 value of 0.3 nM. This compound attenuates the degradation of cyclic guanosine monophosphate (cGMP), thereby facilitating nitric oxide (NO)-induced relaxation of corpus cavernosum smooth muscle and enhancing erectile function. BMS-341400 mesylate serves as a valuable tool for investigating mechanisms underlying erectile dysfunction.

NHTD is a selective inhibitor of KRAS-PDEδ, targeting the prenyl-binding pocket of PDEδ and modulating the cellular localization of KRAS. This action effectively inhibits the proliferation of KRAS-mutant cancer cells and promotes apoptosis. NHTD is a valuable tool for investigations into KRAS-driven non-small cell lung cancer (NSCLC) and related oncology research.

Saterinone is a phosphodiesterase III (PDE III) inhibitor that enhances intracellular cAMP levels, leading to increased vasodilation and improved cardiac function. This compound is significant in cardiovascular research, particularly in studies focused on heart failure and angina. Its role in modulating cAMP signaling pathways makes it an important tool for exploring therapeutic strategies in cardiovascular diseases.

PDE IV-IN-1 is a selective inhibitor of phosphodiesterase IV (PDE4), an enzyme involved in the degradation of cyclic AMP. This compound exhibits anti-inflammatory properties, making it valuable for the research of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), as well as other inflammatory diseases. Its ability to modulate cAMP levels positions PDE IV-IN-1 as a significant tool in the study of inflammatory signaling pathways.

L791943 is a selective phosphodiesterase-4 (PDE4) inhibitor, demonstrating a potent inhibitory effect with an IC50 value of 4.2 nM. This compound is primarily utilized in research aimed at understanding the role of PDE4 in various inflammatory and neurological disorders. Its efficacy in modulating cyclic nucleotide levels makes it a valuable tool for studying signal transduction pathways and therapeutic interventions.

Sch59498 is a potent inhibitor of phosphodiesterase 1C (PDE1C), a phosphodiesterase enzyme involved in cellular signal transduction through the hydrolysis of cyclic nucleotides. This compound demonstrates significant effects on intracellular cAMP and cGMP levels, thereby influencing various physiological processes. Sch59498 is primarily utilized in research applications focused on cardiovascular diseases, neuroprotection, and cancer biology, providing insights into the modulation of signaling pathways associated with these conditions.

Win-62005 is a potent inhibitor of cyclic AMP phosphodiesterase III (PDE III), exhibiting Ki values of 25 nM for rat heart and 26 nM for canine aorta. This compound is primarily utilized in cardiovascular research to explore its effects on cAMP signaling pathways and its potential therapeutic applications in heart conditions. Through the inhibition of PDE III, Win-62005 enhances intracellular cAMP levels, thereby influencing myocardial contractility and vascular tone.

PDE4B/D-IN-5 is a potent inhibitor of phosphodiesterase 4B and 4D, displaying IC50 values of 3.4 nM and 2.2 nM, respectively, with limited central nervous system penetration. This compound effectively inhibits TNF-α production and demonstrates significant anti-inflammatory, antioxidant, and anti-apoptotic properties by reducing the Bax/Bcl2 ratio and mitigating oxidative stress through decreased myeloperoxidase activity and nitric oxide levels. PDE4B/D-IN-5 is suitable for research applications in acute lung injury and related inflammatory conditions.

PDEB1-IN-1 is a selective inhibitor of Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1), exhibiting an IC50 value of 0.95 μM. This compound effectively inhibits the proliferation of T. brucei, with an EC50 of 26 μM, making it a valuable tool for research in trypanosomiasis. PDEB1-IN-1 can be utilized in studies aimed at understanding the role of PDEB1 in the pathogenesis of the disease and for exploring therapeutic avenues in antiparasitic drug development.

ND-7001 is a potent inhibitor of phosphodiesterase 2 (PDE2) with an IC50 value of 0.05 μM, demonstrating significant selectivity against PDE3 and PDE4. This compound effectively elevates cGMP levels in primary neuronal cultures derived from rat cerebral cortical neurons, contributing to its role in modulating neuronal signaling. ND-7001 is primarily utilized in research focused on anxiety disorders and neuropharmacology, highlighting its potential for evaluating anxiolytic mechanisms.

Atrovastatin-PEG3-FITC is a KRAS-PDEδ interaction inhibitor that serves as a valuable tool in the study of KRAS signaling pathways. This compound can function as a ligand in fluorescence anisotropy assays, enabling researchers to investigate protein-protein interactions and their implications in cancer biology. Its application aids in understanding the role of KRAS in various malignancies and exploring potential therapeutic interventions.

D-6-Oxo-pipecolinic acid is the D-enantiomer of 6-Oxo-pipecolinic acid and serves as a biomarker for pyridoxine-dependent epilepsy (PDE) linked to the ALDH7A1 gene. This compound is crucial for studying the metabolic pathways associated with PDE, facilitating research into neurological disorders and potential therapeutic interventions. Its role as a biomarker allows for better understanding and diagnosis of pyridoxine-dependent epilepsy.

Amino Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), acting similarly to its structural analog, tadalafil. It exhibits a significant cross-reactivity of 105.2% with anti-tadalafil polyclonal antibodies, enabling specific detection in various assays. Due to its properties, Amino Tadalafil is suitable for incorporation into dietary supplements and offers potential applications in research exploring erectile dysfunction and cardiovascular health.